Features and treatment options of Chinese hepatocellular carcinoma

Chinese Clinical Oncology

Volumn 2, Issue 4, 2013, Pages

  Wu, Qiong ^a   Qin, Shu Kui ^b  

^a BENGBU MEDICAL COLLEGE   (China)

^b Nanjing Liberation Army 81 Hospital   (China)

Author keywords

China; Etiology; Hepatocellular carcinoma (HCC); Incidence; Personalized therapy

Indexed keywords

EID: 84908510671     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2013.09.07     Document Type: Review

References (26)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010. Available online: http://globocan.iarc.fr
2. Zhang SW, Zheng RS, Li N, et al. Analysis and prediction of liver cancer incidence in China. Zhonghua Yu Fang Yi Xue Za Zhi 2012;46:587-92.
3. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005;5:131-8.
4. Chen PJ, Furuse J, Han KH, et al. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver Int 2010;30:1427-38.
5. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15 Suppl 4:14-22.
6. Liu J, Fan D. Hepatitis B in China. Lancet 2007;369:1582-3.
7. Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011;21:401-16.
8. Cabibbo G, Maida M, Genco C, et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 2012;39:374-83.
9. Yuen MF, Hou JL, Chutaputti A, et al. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24:346-53.
10. Chen WQ, Zhang SW, Zheng RS, et al. Incidence and mortality data analysis of malignant tumor in 2009 in China. Yearbook of Chinese Oncology. Beijing: China Xie-he Medical University Publishing House. 2012:351-64.
11. Thomas MB, O'Beirne JP, Furuse J, et al. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008;15:1008-14.
12. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-81.
13. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421-7.
14. Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004;240:299-305.
15. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8.
16. Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus Doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501-8.
17. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109:1384-90.
18. Mir O, Coriat R, Boudou-Rouquette P, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol 2012;29:2793-9.
19. Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol 2013;58:81-8.
20. Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007;97:862-7.
21. Nagahama H, Okada S, Okusaka T, et al. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol 1997;27:321-4.
22. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
23. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
24. Raoul J, Santoro A, Beaugrand M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial. J Clin Oncol 2008;26:abstr 4587.
25. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821-9.
26. Kelley RK, Venook AP. Novel therapeutics in hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2013:137-42.